Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice
Authors:
- 23 April 2010
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 17 (7) , 512-522
Abstract
Interleukin 12 (IL-12) is a proinflammatory cytokine with antitumor activity. All-trans–retinoic acid (ATRA) exerts antitumor effects by regulating a variety of gene expressions, including tumor necrosis factor receptor 1 (TNFR1), increases the number of TNFR1 and potentiates TNF-α-induced apoptosis in cancer cells. In this study, ATRA-incorporated cationic liposome (ATRA-cationic liposome)/IL-12 plasmid DNA (pDNA) complexes were prepared to improve therapeutic efficacy of cationic liposome/IL-12 pDNA complexes in a mouse model of metastatic lung tumor after intravenous injection. IL-12 production in lungs by ATRA-cationic liposome/IL-12 pDNA complexes was comparable with that by cationic liposome/IL-12 pDNA complexes. The number of metastatic tumor cells (colon26/Luc) was quantitatively evaluated by measuring luciferase activity. ATRA-cationic liposome/IL-12 pDNA complexes reduced the number of colon26/Luc cells and tumor nodules in lungs. ATRA-cationic liposome/IL-12 pDNA complexes significantly prolonged the survival time of mice, whereas cationic liposome/IL-12 pDNA only slightly prolonged it. ATRA-cationic liposome/IL-12 pDNA complexes increased the TNFR1 mRNA upregulation and the number of apoptotic cells in the lung. Moreover, reduced serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were observed in mice treated with ATRA-cationic liposome/IL-12 pDNA complexes. These results suggest that intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes is an effective method for the treatment of lung metastasis in mice.Keywords
This publication has 36 references indexed in Scilit:
- Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in miceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factorsBlood, 2009
- Incorporation of all‐trans retinoic acid into lipoplexes inhibits nuclear factor κB activation mediated liver injury induced by lipoplexes in miceThe Journal of Gene Medicine, 2007
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood, 2007
- All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer PatientsCancer Research, 2006
- Inhibition of Metastatic Tumor Growth in Mouse Lung by Repeated Administration of Polyethylene Glycol-Conjugated CatalaseClinical Cancer Research, 2004
- Retinoids in cancer therapy and chemoprevention: promise meets resistanceOncogene, 2003
- Therapeutic effect of all-trans retinoic acid on rats with anti-GBM antibody glomerulonephritisKidney International, 2003
- All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-κB, activated protein-1 and apoptosis in human lung cancer cellsOncogene, 2000
- Synergistic stimulation of MHC class I and IRF‐1 gene expression by IFN‐γ and TNF‐α in oligodendrocytesEuropean Journal of Neuroscience, 1998